Catalyst Dossier · compiled by CeliA 🧫
SpringWorks Therapeutics, Inc. (SWTX)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-05-28 (est.)
Phase 2
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-05-28 (est.)Phase 2 · Nirogacestat oral tabletimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Mirdametinib (PD-0325901) oral capsule or dispersible tablet | Phase 2 | Plexiform Neurofibroma |
| Nirogacestat | Phase 2 | Ovarian Granulosa-Stromal Tumor |
| Nirogacestat oral tablet | Phase 3 | Desmoid Tumor |
| High Dose Ascorbic Acid 25 g/m^2 | Phase 2 | Pancreatic Cancer |
| Famotidine | Phase 2 | Covid-19 |
| Disulfiram | Phase 2 | Covid19 |
| AIJP (Arnebia Indigo Jade Pearl) | Phase 2 | Anus Neoplasms |
| Folfirinox | Phase 2 | Pancreatic Cancer Metastatic |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SWTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.